Potential of gene expression profiling in the management of childhood acute lymphoblastic leukemia

Pediatric Drugs

Volumn 9, Issue 3, 2007, Pages 149-156

  Bhojwani, Deepa ^a,b   Moskowitz, Naomi ^a   Raetz, Elizabeth A ^a,b   Carroll, William L ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; DAUNORUBICIN; METHOTREXATE; METHOTREXATE POLYGLUTAMATE; PREDNISOLONE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADVERSE OUTCOME; CANCER CLASSIFICATION; CANCER RELAPSE; CHROMOSOME ANALYSIS; COST BENEFIT ANALYSIS; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; DNA MICROARRAY; DRUG TARGETING; EARLY INTERVENTION; GENE EXPRESSION PROFILING; HIGH THROUGHPUT SCREENING; HUMAN; LEUKEMOGENESIS; METHODOLOGY; OUTCOME ASSESSMENT; PATIENT IDENTIFICATION; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; RISK FACTOR; TREATMENT RESPONSE; VALIDATION PROCESS;

CHILD; DIPLOIDY; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENE PROTEINS; POLYMORPHISM, GENETIC; RECURRENCE;

EID: 34249802352     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00148581-200709030-00003     Document Type: Review

References (36)

1. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006; 354 (2): 166-78
2. Borowitz MJ, Pullen DJ, Shuster JJ, et al. Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children's Oncology Group study. Leukemia 2003; 17 (8): 1566-72
3. Raetz EA, Bhojwani D, Carroll WL, et al. Individualized therapy for childhood acute lymphoblastic leukemia. Personalized Med 2005; 2 (4): 349-61
4. Arico M, Valsecchi MG, Conter V, et al. Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin-Frankfurt-Muenster protocol II. Blood 2002; 100 (2): 420-6
5. Silverman LB, Sallan SE. Newly diagnosed childhood acute lymphoblastic leukemia: update on prognostic factors and treatment. Curr Opin Hematol 2003; 10 (4): 290-6
6. Gaynon PS. Childhood acute lymphoblastic leukaemia and relapse. Br J Haematol 2005; 131 (5): 579-87
7. Robison LL, Bhatia S. Late-effects among survivors of leukaemia and lymphoma during childhood and adolescence. Br J Haematol 2003; 122 (3): 345-59
8. Arico M, Conter V, Valsecchi MG, et al. Treatment reduction in highly selected standard-risk childhood acute lymphoblastic leukaemia: the AIEOP ALL-9501 study. Haematologica 2005; 90 (9): 1186-91
9. Pieters R, den Boer ML, Durian M, et al. Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukaemia: implications for treatment of infants. Leukemia 1998; 12 (9): 1344-8
10. Johansson B, Mertens F, Mitelman F. Clinical and biological importance of cytogenetic abnormalities in childhood and adult acute lymphoblastic leukemia. Ann Med 2004; 36 (7): 492-503
11. Cheok MH, Evans WE. Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy. Nat Rev Cancer 2006; 6 (2): 117-29
12. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999; 286 (5439): 531-7
13. Brazma A, Hingamp P, Quackenbush J, et al. Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet 2001; 29 (4): 365-71
14. Mitchell SA, Brown KM, Henry MM, et al. Inter-platform comparability of microarrays in acute lymphoblastic leukemia. BMC Genomics 2004; 5 (1): 71
15. van Delft FW, Bellotti T, Luo Z, et al. Prospective gene expression analysis accurately subtypes acute leukaemia in children and establishes a commonality between hyperdiploidy and t(12;21) in acute lymphoblastic leukaemia. Br J Haematol 2005; 130 (1): 26-35
16. Yeoh EJ, Ross ME, Shurtleff SA, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002; 1 (2): 133-43
17. Kohlmann A, Schoch C, Schnittger S, et al. Pediatric acute lymphoblastic leukemia (ALL) gene expression signatures classify an independent cohort of adult ALL patients. Leukemia 2004; 18 (1): 63-71
18. Cario G, Stanulla M, Fine BM, et al. Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia. Blood 2005; 105 (2): 821-6
19. Flotho C, Coustan-Smith E, Pei D, et al. Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2. Blood 2006; 108 (3): 1050-7
20. Holleman A, Cheok MH, den Boer ML, et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med 2004; 351 (6): 533-42
21. Lugthart S, Cheok MH, den Boer ML, et al. Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia. Cancer Cell 2005; 7 (4): 375-86
22. Kager L, Cheok M, Yang W, et al. Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. J Clin Invest 2005; 115 (1): 110-7
23. Holleman A, den Boer ML, de Menezes RX, et al. The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia. Blood 2006; 107 (2): 769-76
24. Bogni A, Cheng C, Liu W, et al. Genome-wide approach to identify risk factors for therapy-related myeloid leukemia. Leukemia 2006; 20 (2): 239-46
25. Edick MJ, Cheng C, Yang W, et al. Lymphoid gene expression as a predictor of risk of secondary brain tumors. Genes Chromosomes Cancer 2005; 42 (2): 107-16
26. Ferrando AA, Neuberg DS, Staunton J, et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 2002; 1 (1): 75-87
27. Palomero T, Odom DT, O'Neil J, et al. Transcriptional regulatory networks downstream of TAL1/SCL in T-cell acute lymphoblastic leukemia. Blood 2006; 108 (3): 986-92
28. Hilden JM, Dinndorf PA, Meerbaum SO, et al. Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group. Blood 2006; 108 (2): 441-51
29. Armstrong SA, Staunton JE, Silverman LB, et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 2002; 30 (1): 41-7
30. Stam RW, den Boer ML, Schneider P, et al. Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia. Blood 2005; 106 (7): 2484-90
31. Armstrong SA, Kung AL, Mabon ME, et al. Inhibition of FLT3 in MLL: validation of a therapeutic target identified by gene expression based classification. Cancer Cell 2003; 3 (2): 173-83
32. Stam RW, den Boer ML, Passier MM, et al. Silencing of the tumor suppressor gene FHIT is highly characteristic for MLL gene rearranged infant acute lymphoblastic leukemia. Leukemia 2006; 20 (2): 264-71
33. Bhojwani D, Kang H, Moskowitz NP, et al. Biological pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group study. Blood 2006; 108 (2): 711-7
34. Beesley AH, Cummings AJ, Freitas JR, et al. The gene expression signature of relapse in paediatric acute lymphoblastic leukaemia: implications for mechanisms of therapy failure. Br J Haematol 2005; 131 (4): 447-56
35. Draghici S, Khatri P, Eklund AC, et al. Reliability and reproducibility issues in DNA microarray measurements. Trends Genet 2006; 22 (2): 101-9
36. Schwerk C, Schulze-Osthoff K. Regulation of apoptosis by alternative pre-mRNA splicing. Mol Cell 2005; 19 (1): 1-13